Over-correction avoided by administering correct dosage

Article

Over-correction in children with intermittent exotropia can be avoided by using the correct surgical dosage.

Over-correction in children with intermittent exotropia can be avoided by using the correct surgical dosage.

A team led by Dr Deborah Buck, Institute of Neuroscience, Medical School, Newcastle University, Newcastle upon Tyne, UK, included 87 children with intermittent exotropia who underwent surgery in 18 centres across the UK.

Primary outcome measures included motor/sensory outcome and the secondary outcome measure was satisfactory control assessed by the Newcastle Control Score (NCS).

Of the 87 children studied, 72 were available for review data. Preoperative and surgical characterisitics had no effect on the primary outcome and satisfactory control was achieved in 65% of patients, whilst 20% still had intermittent extropia.

It was discovered that 35%, 28% and 37% of patients had excellent, fair and poor primary outcomes, respectively. Persistent over-correction was found in 15% of the patients and there was no recorded relationship between over-correction and preoperative characteristics or surgical dose/type.

At near and distance visions the median angle improved by 12 prism dioptres (PD) and 19 PD, respectively. The median NCS improved by five and the 40% who were initiallt over-corrected remained over-corrected by the last postoperative assessment.

The abstract was published in the latest issue of the British Journal of Ophthalmology.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.